Poole, C.J., Earl, H.M., Hiller, L., Dunn, J.A., Bathers, S., Grieve, R.J., ...
BACKGROUND: The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer. METHODS: In NEAT, we compared...
Smith, I. E., AHern, R. P., Coombes, G. A., Howell, A., Ebbs, S. R., Hickish, T. F., ...
Background: To compare the efficacy of continuous infusional 5-fluorouracil (5-FU)-based chemotherapy against conventional bolus chemotherapy in the preoperative treatment of patients with large...
Lofts, F. J., Gogas, H., Mansi, J. L.
Background: Adenocarcinoma of unknown primary comprises up to 10% of metastatic malignant disease. With few exceptions this diagnosis carries a very poor prognosis of a few months with minimal...
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer (1995)
Smyth, J. F., Hardcastle, J. D., Denton, G., Alderson, D., Grace, R. H., Mansi, J. L., ...
Findlay, M. P. N., Leach, M. O., Cunningham, D., Collins, D. J., Payne, G. S., Glaholm, J., ...
Background: 5-Fluorouracil (5-FU) is the most widely used cytotoxic drug in oncology and the only one useful in the management of colorectal cancer - a leading cause of cancer death worldwide. Recent...
Mansi, J L, Berger, U, Easton, D, McDonnell, T, Redding, W H, Gazet, J C, ...
The bone marrow of 307 patients with primary breast cancer was examined for tumour cells by immunocytochemistry using an antiserum to epithelial membrane antigen. Micrometastases were found in 81...
Mansi, J L, Berger, U, Easton, D, McDonnell, T, Redding, W H, Gazet, J C, ...
The bone marrow of 307 patients with primary breast cancer was examined for tumour cells by immunocytochemistry using an antiserum to epithelial membrane antigen. Micrometastases were found in 81...
Myeloma and benign intracranial hypertension.
Wasan, H., Mansi, J. L., Benjamin, S., Powles, R., Cunningham, D.
Adjuvant chemotherapy for colorectal cancer.
Rayter, Z., Leicester, R. J., Mansi, J. L.
Colorectal cancer is the second most common cancer in the Western world, and yet the survival after potentially curative excisional surgery has improved little over the last half century. Newer...
Granulocytic sarcoma: a diagnosis to be considered in unusual lymphoma syndromes.
Mansi, J. L., Selby, P. J., Carter, R. L., Powles, R. L., McElwain, T. J.
A series of 7 patients with granulocytic sarcoma is presented to illustrate its varied clinical picture. In particular, this condition may present with features which suggest a non-Hodgkin lymphoma....
Repeat administration of high dose melphalan in relapsed myeloma.
Mansi, J. L., Cunningham, D., Viner, C., Ellis, E., Meldrum, M., Milan, S., ...
At a median time of 20 months following high dose melphalan for myeloma, 29 patients relapsed and were treated with induction chemotherapy to maximum response followed by a second course of high dose...
Seymour, M. T., Mansi, J. L., Gallagher, C. J., Gore, M. E., Harper, P. G., Evans, T. R., ...
This phase II study evaluates the efficacy and toxicity of a prolonged schedule of oral etoposide in patients with measurable advanced ovarian cancer resistant to, or relapsed following,...
Jodrell, D. I., Smith, I. E., Mansi, J. L., Pearson, M. C., Walsh, G., Ashley, S., ...
Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer. We have compared MMM...
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi, J. L., De Graeff, A., Newell, D. R., Glaholm, J., Button, D., Leach, M. O., ...
Lonidamine is a substituted indazole carboxylic acid with a unique mechanism of action and early clinical studies have reported anti-tumour activity. In a phase II study 32 patients with previously...
Evans, T. R., Lofts, F. J., Mansi, J. L., Glees, J. P., Dalgleish, A. G., Knight, M. J.
Carcinomas of the exocrine pancreas respond poorly to most chemotherapy regimens. Recently continuous infusional 5-fluorouracil (200 mg m-(2)day-1) with 3 weekly cisplatin (60 mg m-2) and epirubicin...
Gogas, H., Lofts, F. J., Evans, T. R., Daryanani, S., Mansi, J. L.
Thirty-nine patients with inoperable adenocarcinoma of the pancreas were studied (27 male, 12 female; median age 60 years, range 39-75 years). All patients received chemotherapy with continuous...
Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.
Gogas, H., Lofts, F. J., Evans, T. R., Millard, F. J., Wilson, R., Mansi, J. L.
To assess the efficacy and toxicity of an outpatient combination chemotherapy in small-cell lung cancer (SCLC), we treated 70 consecutive patients with epirubicin 80 mg m(-2) i.v. on day 1 and...
Primrose, J N, Bleiberg, H, Daniel, F, Belle, S Van, Mansi, J L, Seymour, M, ...
Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with...
Bisphosphonates induce apoptosis in human breast cancer cell lines
Senaratne, S G, Pirianov, G, Mansi, J L, Arnett, T R, Colston, K W
Breast cancer has a prodigious capacity to metastasize to bone. In women with advanced breast cancer and bone metastases, bisphosphonates reduce the incidence of hypercalcaemia and skeletal...
Bretherton-Watt, D, Given-Wilson, R, Mansi, J L, Thomas, V, Carter, N, Colston, K W
There is increasing evidence that vitamin D can protect against breast cancer. The actions of vitamin D are mediated via the vitamin D receptor (VDR). We have investigated whether polymorphisms in...
Evans, T R J, Colston, K W, Lofts, F J, Cunningham, D, Anthoney, D A, Gogas, H, ...
Inoperable cancer of the exocrine pancreas responds poorly to most conventional anti-cancer agents, and new agents are required to palliate this disease. Seocalcitol (EB1089), a vitamin D analogue,...
Senaratne, S G, Mansi, J L, Colston, K W
Bisphosphonates are well established in the management of cancer-induced bone disease. Recent studies have indicated that these compounds have direct inhibitory effects on cultured human breast...
Senaratne, S G, Mansi, J L, Colston, K W
British Journal of Cancer (2002) 87, 1340–1340. doi:10.1038/sj.bjc.6600571 www.bjcancer.com